Ace Infectious follows the drug development trend of H. pylori therapeutic peptides and proteins (TPPs) and provides screening and discovery services for H. pylori TPPs to help accelerate the development of therapeutic drugs for treating H. pylori.
Currently, a variety of peptides and proteins have been found useful in the treatment of H. pylori. One of the most studied is the antimicrobial peptide. Neshani et al. (2019) searched several authoritative literature databases and found 22 anti-H. pylori antimicrobial peptides. Most of these antimicrobial peptides have α-helical structure (Fig. 1), and pexiganan, tilapia piscidin 4 (TP4), and PGLa-AM1 were more active. Later, Cbf-K16, HF-18, and peptides extracted from a green alga were also found to have inhibitory activity against H. pylori. In addition, bovine milk casein, after digesting by pepsin, has an inhibitory effect on H. pylori. Overall, there is a positive trend in the development of TPPs against H. pylori.
Fig. 1 Most of these antimicrobial peptides have α-helical structure (Neshani et al., 2019).
We help accelerate the development of H. pylori TPPs and provide customized services. Firstly, we provide services to screen peptides and proteins for the treatment of H. pylori from those already available in the organism. Then, we provide peptide and protein discovery services that target specific therapeutic objectives of H. pylori. Furthermore, we provide services to discover recombinant proteins and macrocyclic peptides that are therapeutically effective against H. pylori.
Our strengths in three aspects make us more efficient in screening and discovery of H. pylori TPPs. These are various screening and discovery methods, specialized protein-based databases, and well-established protein extraction and expression systems.
Various screening and discovery methods
We offer three main strategies for the screening and discovery of TPPs against H. pylori. High-throughput screening methods are used to discover TPPs that are derived from organisms. Ligand-receptor development methods are used to discover TPPs for specific therapeutic targets. Structure-based design approaches are used to discover recombinant proteins and macrocyclic peptides to treat H. pylori. In addition, when targeting specific protein therapeutic targets for the discovery of TPPs, we offer discovery services targeting structural domains, linking structural domains, and specific pocket structures. What's more, in screening organism peptides and proteins, we offer screening services performed under gastric degradation conditions.
Specialized protein-based databases
To facilitate the screening of H. pylori TPPs, peptide or protein databases have been established. We firstly established a database of known antimicrobial peptides to discover antimicrobial peptides with anti-H. pylori activity. We then established a database of peptides and proteins from bacteriophages and probiotics as they have anti-H. pylori effects and we also established a database of peptides and proteins from other anti-H. pylori organisms. Further, we established a database of domains and peptides obtained from the degradation of natural proteins in the gastric environment.
Well-established protein extraction and expression systems
We have sophisticated methods for peptide and protein extraction, including general extraction methods such as salinization, gel filtration, and isoelectric precipitation, and precise purification methods such as high-performance liquid chromatography, capillary electrophoresis, and affinity chromatography.
In the services of preparation and custom synthesis for H. pylori vaccine antigens, we introduced four expression systems, namely E. coli expression system, L. lactis expression system, P. pastoris expression system, and attenuated Salmonella expression system. We appropriately use these systems to express peptides and proteins (especially recombinant proteins) to discover those with properties for the treatment of H. pylori infection. In addition, we also use some plant, insect cell, and baculovirus expression systems to help discover TPPs against H. pylori.
Ace Infectious assists in the screening and discovery of TPPs for the treatment of H. pylori infection. We help to discover TPPs that have the effect of inhibiting the virulence factor of H. pylori, reducing H. pylori colonization, reducing inflammation, and inhibiting the growth of H. pylori. Please contact us for therapeutic peptide and protein discovery services targeting H. pylori.
- Neshani, A.; et al. Review of antimicrobial peptides with anti-Helicobacter pylori activity. Helicobacter. 2019, 24(1): e12555.
- Wan, G.; et al. Extraction of antibacterial peptides against Helicobacter pylori from bovine milk casein. Arch Med Sci. 2022, 18(2): 376-81.
※ All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.